How it works: Medicines for NMOSD and MOGAD →

Enspryng

EU: Approved in the EU since 2021US: FDA approved 2020

Molecule type
Antibody
Mechanism (ChEMBL)
IL6Ralpha/GP130 antagonist
Targets
IL6Ralpha/GP130
Availability
Authorised in all EU and EEA countries. Reimbursement is decided by each country.

Approvals

  • USEnspryng · Approved14 August 2020 Source
  • EU/EEAEnspryng · Authorised24 June 2021 Source

Safety communications

None recorded.

Most-reported side effects (FDA reports)

Reports to the FDA's adverse event system (FAERS) show what people and doctors reported while taking the medicine. They do not prove the medicine caused it, and they are not rates.

322 reports in total, 301 marked serious.

  • Neuromyelitis optica spectrum disorder80
  • Off label use60
  • Urinary tract infection34
  • Muscular weakness22
  • Hypoaesthesia20
  • Pneumonia20
  • Infection19
  • Fatigue18
  • Optic neuritis18
  • Covid-1914

Trials

Key trials

Large trials with a reported result on their main goal.

Running now

Other trials (2)

Completed small trials, dose-finding studies and trials in other diseases.

For information only, not medical advice. Talk to your neurologist before changing treatment.

Hypotheses involving this medicine

Loading hypotheses…

Loading reviews and guidelines…

Lab studies

Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.

Loading lab studies…

Assembled by software from public sources.